Patents by Inventor Nasreen Khalil

Nasreen Khalil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Post-translational activation of TGF-.beta..sub.1 involving the TSP-1 receptor CD36
    Patent number: 6090367
    Abstract: A protein called transforming growth factor-beta (TGF-.beta.) is important in causing the inflammation and progressive scar tissue in pulmonary fibrosis. The TGF-.beta..sub.1 isoform is important in the pathogenesis of pulmonary fibrosis. It is usually secreted non-covalently bound to a latency associated peptide (LAP) which renders it biologically inactive. The inactive form is called latent TGF-.beta..sub.1 (L-TGF-.beta..sub.1). Activation of L-TGF-.beta..sub.1 involves L-TGF-.beta..sub.1 /TSP-1 complex which interacts with the TSP-1 receptor, CD36, to process L-TGF-.beta..sub.1 to the mature form in the presence of plasmin. Synthetic or natural CD36 peptides or fragments thereof can be used to prevent activation of TGF-.beta..sub.1, in mammalian alveolar macrophages, thereby controlling the inflammation process.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: July 18, 2000
    Assignees: Manitoba Cancer Treatment and Research Foundation, The University of Manitoba
    Inventor: Nasreen Khalil